Business
Neural Therapeutics Announces Filing and Mailing of Meeting Materials for Annual and Special Meeting to Approve Series B Transactions with CWE
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its notice of annual and special meeting, management information circular and related meeting materials (collectively, the "Meeting Materials") in...
About this update from Neural Therapeutics Inc.
[{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its notice of annual and special meeting, management information circular and related meeting materials (collectively, the "Meeting Materials") in connection with the Company's annual and special meeting of shareholders (the "Meeting"), to be held on May 25, 2026 at 10:00 a.m. (Toronto time).","length":683,"tagName":"p"},{"type":"text","content":"On August 12, 2025, Neural acquired a 30.75% ownership interest in CWE, providing Neural with indirect exposure to the operations of CWE European Holdings Inc. ("CWE") (see Neural press releases dated August 13, 2025 and May 28, 2025). The Meeting Materials are available under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at www.neuraltherapeutics.ca.","length":406,"tagName":"p"},{"type":"text","content":"The Meeting Materials have been distributed to shareholders in accordance with applicable securities laws and the Company's notice-and-access procedures. Shareholders are encouraged to review the Meeting Materials in full before voting.","length":240,"tagName":"p"},{"type":"text","content":"At the Meeting, shareholders will be asked to consider and, if deemed advisable, approve a number of matters, including:","length":120,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"the acquisition by Neural of the remaining 69.25% equity interest in CWE not already owned by the Company and the ancillary transactions relating thereto (the "Series B Transactions");","length":194,"tagName":"p"}]},{"val":[{"type":"text","content":"a consolidation of the Company's common shares on the basis of one (1) post-consolidation common share for every four (4) pre-consolidation common shares;","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"a change of name of the Company to "Hanf.com Inc." or such other name as may be approved by the board of directors and the Canadian Securities Exchange;","length":162,"tag...